PART I Overview Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology (ENHANZE) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced trea...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001159036-26-000024 | EDGAR | 75K words |
| 2025-02-18 | 2024-12-31 | 0001159036-25-000010 | EDGAR | — |
| 2024-02-20 | 2023-12-31 | 0001159036-24-000008 | EDGAR | — |
| 2023-02-21 | 2022-12-31 | 0001159036-23-000012 | EDGAR | — |
| 2022-02-22 | 2021-12-31 | 0001159036-22-000014 | EDGAR | — |
| 2021-02-23 | 2020-12-31 | 0001159036-21-000014 | EDGAR | — |
| 2020-02-24 | 2019-12-31 | 0001159036-20-000013 | EDGAR | — |
| 2019-02-21 | 2018-12-31 | 0001159036-19-000006 | EDGAR | — |
| 2018-02-20 | 2017-12-31 | 0001159036-18-000011 | EDGAR | — |
| 2017-02-28 | 2016-12-31 | 0001159036-17-000014 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-03 | 2025-09-30 | 0001159036-25-000045 | EDGAR | 34K words |
| 2025-08-05 | 2025-06-30 | 0001159036-25-000034 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001159036-25-000026 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001159036-24-000050 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001159036-24-000044 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001159036-24-000037 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001159036-23-000057 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001159036-23-000048 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001159036-23-000039 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001159036-22-000059 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001159036-22-000050 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001159036-22-000038 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001159036-26-000035 | EDGAR | 1K words |
| 2026-02-17 | 0001159036-26-000023 | EDGAR | — |
| 2026-01-28 | 0001159036-26-000011 | EDGAR | — |
| 2025-12-09 | 0001159036-25-000070 | EDGAR | — |
| 2025-12-08 | 0001159036-25-000068 | EDGAR | — |
| 2025-11-24 | 0001159036-25-000061 | EDGAR | — |
| 2025-11-12 | 0001193125-25-277988 | EDGAR | — |
| 2025-11-07 | 0001159036-25-000049 | EDGAR | — |
| 2025-11-05 | 0001159036-25-000047 | EDGAR | — |
| 2025-11-03 | 0001159036-25-000044 | EDGAR | — |
271 total filings indexed. 239 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001159036 |
| Ticker | HALO |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.halozyme.com |
| Listed | 2004-03-12 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report